Concepedia

Howard Fox

HF

Statistics

Publications

9

Citations

888

H-Index

9

Active since

1915

Affiliations

Novartis (United Kingdom)(Current)

Novartis (United States)

National Jewish Health

Hôpital Arnaud de Villeneuve

University of Colorado Denver

Howard Fox is an author at Novartis (United Kingdom) specializing in allergy, omalizumab therapy, and allergic disease.

Publications per year

1915–2006

9

Publications

9

Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma

Jean Bousquet, Sally E. Wenzel, Stephen T. Holgate et al. · CHEST Journal · 2004 · 276 citations

, , +14

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

Paul Chervinsky, Thomas B. Casale, Robert G. Townley et al. · Annals of Allergy Asthma & Immunology · 2003 · 213 citations

, , +14

Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma

Günther Hochhaus, L Brookman, Howard Fox et al. · Current Medical Research and Opinion · 2003 · 183 citations

, , +17

Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and Mortality

Stephen T. Holgate, Jean Bousquet, Sally E. Wenzel et al. · Current Medical Research and Opinion · 2001 · 117 citations

, , +17

Improvement in quality of life with omalizumab in patients with severe allergic asthma

Bradley E. Chipps, Roland Buhl, Kai-Michael Beeh et al. · Current Medical Research and Opinion · 2006 · 46 citations

, , +17

1–5 of 9